JOHN CHARLES ARAUJO

TitleAssociate Professor
InstitutionMD Anderson
DepartmentGenitourinary Medical Oncology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Anselmino N, Labanca E, Shepherd PDA, Dong J, Yang J, Song X, Nandakumar S, Kundra R, Lee CJ, Schultz N, Zhang J, Araujo JC, Aparicio AM, Subudhi SK, Corn PG, Pisters LL, Ward JF, Davis JW, Vazquez ES, Gueron G, Logothetis CJ, Futreal A, Troncoso P, Chen Y, Navone NM. Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series. Clin Cancer Res. 2024 Mar 15. PMID: 38488813.
      Citations:    Fields:    
    2. Halabi S, Yang Q, Roy A, Luo B, Araujo JC, Logothetis C, Sternberg CN, Armstrong AJ, Carducci MA, Chi KN, de Bono JS, Petrylak DP, Fizazi K, Higano CS, Morris MJ, Rathkopf DE, Saad F, Ryan CJ, Small EJ, Kelly WK. External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Na?ve Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 05 20; 41(15):2736-2746. PMID: 37040594; PMCID: PMC10414709.
      Citations: 1     Fields:    Translation:Humans
    3. Labanca E, Anselmino N, Yang J, Shepherd PDA, Hoang AG, Tang X, Raso MG, Titus M, Efstathiou E, Araujo J, Logothetis C, Navone N, Bizzotto J, Sanchis P, Paez A, Antico-Arciuch V, Lage-Vickers S, Cotignola J, Vazquez E, Gueron G. Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel. Oncogene. 2021 11; 40(44):6284-6298. PMID: 34584218; PMCID: PMC8566229.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    4. Spetsieris N, Boukovala M, Alafis I, Davis J, Zurita A, Wang X, Tu SM, Chapin BF, Aparicio A, Corn P, Wang J, Subudhi SK, Araujo J, Papadopoulos J, Pruitt L, Weldon JA, Logothetis CJ, Efstathiou E. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-na?ve prostate cancer. Eur J Cancer. 2021 11; 157:259-267. PMID: 34536949.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    5. Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. Int J Cancer. 2021 07 15; 149(2):387-393. PMID: 33739450.
      Citations: 2     Fields:    Translation:Humans
    6. Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851. PMID: 33046869.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    7. Palanisamy N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, Labanca E, Manyam GC, Ravoori MK, Kundra V, Araujo JC, Efstathiou E, Pisters LL, Wan X, Wang X, Vazquez ES, Aparicio AM, Carskadon SL, Tomlins SA, Kunju LP, Chinnaiyan AM, Broom BM, Logothetis CJ, Troncoso P, Navone NM. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. Clin Cancer Res. 2020 09 15; 26(18):4933-4946. PMID: 32576626; PMCID: PMC7501166.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    8. Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wang X, Wen S, Efstathiou E. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2021 02; 19(1):22-31.e5. PMID: 32675015; PMCID: PMC10014037.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    9. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, De Bono JS, Araujo JC, Logothetis C, Eisenberger MA, Quinn DI, Fizazi K, Morris MJ, Higano CS, Tannock IF, Small EJ, Kelly WK. Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. JNCI Cancer Spectr. 2020 Apr; 4(2):pkaa003. PMID: 32368717; PMCID: PMC7190204.
      Citations:    Fields:    
    10. Boukovala M, Spetsieris N, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wen S, Efstathiou E. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2020 03; 127:67-75. PMID: 31986451; PMCID: PMC7350510.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    11. Efstathiou E, Titus M, Wen S, Troncoso P, Hoang A, Corn P, Prokhorova I, Araujo J, Dmuchowski C, Melhem-Bertrandt A, Patil S, Logothetis CJ. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients. Eur Urol Oncol. 2020 02; 3(1):119-127. PMID: 31412017; PMCID: PMC7204265.
      Citations: 8     Fields:    Translation:Humans
    12. Duplisea JJ, Petros FG, Li R, Fellman B, Guo CC, Czerniak BA, Siefker-Radtke AO, Araujo JC, Dinney CPN, Matin SF. Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urol Oncol. 2019 06; 37(6):354.e19-354.e26. PMID: 30777393; PMCID: PMC6511295.
      Citations: 3     Fields:    Translation:Humans
    13. Etchebehere E, Kairemo K, Rohren E, Araujo J, Macapinlac H, Brito AE. Is interim 18F-fluoride PET/CT a predictor of outcomes after radium-223 therapy? Radiol Bras. 2019 Jan-Feb; 52(1):33-40. PMID: 30804613; PMCID: PMC6383535.
      Citations: 3     
    14. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, Araujo JC, Logothetis C, Quinn DI, Fizazi K, Morris MJ, Eisenberger MA, George DJ, De Bono JS, Higano CS, Tannock IF, Small EJ, Kelly WK. Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. J Clin Oncol. 2019 02 10; 37(5):403-410. PMID: 30576268; PMCID: PMC6804881.
      Citations: 31     Fields:    Translation:Humans
    15. Corn PG, Agarwal N, Araujo JC, Sonpavde G. Taxane-based Combination Therapies for Metastatic Prostate Cancer. Eur Urol Focus. 2019 05; 5(3):369-380. PMID: 29275145.
      Citations: 9     Fields:    Translation:Humans
    16. Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol. 2017 Sep; 80(3):583-589. PMID: 28730293.
      Citations: 2     Fields:    Translation:Humans
    17. Maity SN, Titus MA, Gyftaki R, Wu G, Lu JF, Ramachandran S, Li-Ning-Tapia EM, Logothetis CJ, Araujo JC, Efstathiou E. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. Sci Rep. 2016 10 17; 6:35354. PMID: 27748439; PMCID: PMC5066251.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    18. Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Allison JP, Sharma P. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A. 2016 10 18; 113(42):11919-11924. PMID: 27698113; PMCID: PMC5081579.
      Citations: 86     Fields:    Translation:HumansCells
    19. Dayyani F, Zurita AJ, Slack R, Millikan RE, Araujo JC, Gallick GE, Logothetis CJ, Corn PG, Nogueras-Gonz?lez GM. The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study. BMC Cancer. 2016 09 06; 16:721. PMID: 27599544; PMCID: PMC5013640.
      Citations: 6     Fields:    Translation:Humans
    20. Araujo JC, Erwin WD, Wendt RE, Swanston NM, Fox P, Macapinlac HA, Rohren EM, Etchebehere EC, Milton DR. Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy. Clin Nucl Med. 2016 Apr; 41(4):268-73. PMID: 26828141.
      Citations: 7     Fields:    Translation:Humans
    21. Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn DI, Morris MJ, Higano CS, Tannock IF, Small EJ. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol. 2016 05 10; 34(14):1652-9. PMID: 26951312; PMCID: PMC4872320.
      Citations: 118     Fields:    Translation:Humans
    22. Etchebehere EC, Araujo JC, Swanston NM, Macapinlac HA, Rohren EM, Milton DR. Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution. Eur J Nucl Med Mol Imaging. 2016 Jan; 43(1):8-20. PMID: 26416392.
      Citations: 21     Fields:    Translation:Humans
    23. Rohren EM, Etchebehere EC, Araujo JC, Hobbs BP, Swanston NM, Everding M, Moody T, Macapinlac HA. Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT. J Nucl Med. 2015 Oct; 56(10):1507-12. PMID: 26135112; PMCID: PMC5025941.
      Citations: 31     Fields:    Translation:Humans
    24. Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. J Nucl Med. 2015 Aug; 56(8):1177-84. PMID: 26069307.
      Citations: 48     Fields:    Translation:Humans
    25. Varkaris A, Katsiampoura AD, Araujo JC, Gallick GE, Corn PG. Src signaling pathways in prostate cancer. Cancer Metastasis Rev. 2014 Sep; 33(2-3):595-606. PMID: 24522479; PMCID: PMC4640186.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    26. Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer. 2015 Jan 01; 121(1):69-76. PMID: 25155428; PMCID: PMC4270821.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    27. Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 2014 Mar 15; 74(6):1651-60. PMID: 24473064; PMCID: PMC4009928.
      Citations: 136     Fields:    Translation:HumansAnimalsCells
    28. Araujo JC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ, Trudel GC. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013 Dec; 14(13):1307-16. PMID: 24211163; PMCID: PMC5478530.
      Citations: 94     Fields:    Translation:HumansCTClinical Trials
    29. Tamboli P, Ng CS, Lin E, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM, Richey SL. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol. 2013 Oct; 36(5):450-4. PMID: 22706175; PMCID: PMC3882166.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    30. Ng L, Heck W, Lavsa S, Crowther D, Atkinson B, Xiao L, Araujo J. The lack of predictors for rapid progression in prostate cancer patients receiving sipuleucel-T. Cancers (Basel). 2013 May 06; 5(2):511-8. PMID: 24216988; PMCID: PMC3730335.
      Citations: 3     
    31. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3621-30. PMID: 23649003; PMCID: PMC3699964.
      Citations: 136     Fields:    Translation:Humans
    32. Araujo JC, Trudel GC, Paliwal P. Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel. Cancer Manag Res. 2013; 6:25-30. PMID: 23516140; PMCID: PMC3601649.
      Citations: 10     
    33. Eser PO, Vanden Heuvel JP, Araujo J, Thompson JT. Marine- and plant-derived ?-3 fatty acids differentially regulate prostate cancer cell proliferation. Mol Clin Oncol. 2013 May; 1(3):444-452. PMID: 24649190; PMCID: PMC3916163.
      Citations: 12     
    34. Dayyani F, Varkaris A, Araujo JC, Song JH, Chatterji T, Trudel GC, Logothetis CJ, Gallick GE. Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer. Prostate. 2013 Jun; 73(9):979-85. PMID: 23371521; PMCID: PMC4013833.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    35. Ameri H, Araujo JC, Gombos DS. Leuprolide monotherapy for choroidal metastasis from prostate adenocarcinoma. Arch Ophthalmol. 2012 Sep; 130(9):1225-6. PMID: 22965610.
      Citations: 1     Fields:    Translation:Humans
    36. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2012 Dec; 62(6):1013-9. PMID: 22771265; PMCID: PMC3882163.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    37. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011 Nov 30; 3(111):111ra121. PMID: 22133722; PMCID: PMC3476478.
      Citations: 259     Fields:    Translation:HumansAnimalsCells
    38. Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Paliwal P, Agrawal S, Logothetis CJ, Trudel GC. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer. 2012 Jan 01; 118(1):63-71. PMID: 21976132; PMCID: PMC3898168.
      Citations: 69     Fields:    Translation:HumansCTClinical Trials
    39. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate. 2011 Jun 01; 71(8):846-56. PMID: 21456067; PMCID: PMC3883511.
      Citations: 39     Fields:    Translation:HumansAnimals
    40. Araujo J, Logothetis C. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev. 2010 Oct; 36(6):492-500. PMID: 20226597; PMCID: PMC3940067.
      Citations: 91     Fields:    Translation:HumansAnimals
    41. Araujo JC, Poblenz A, Corn P, Parikh NU, Starbuck MW, Thompson JT, Lee F, Logothetis CJ, Darnay BG. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation. Cancer Biol Ther. 2009 Nov; 8(22):2153-9. PMID: 19855158; PMCID: PMC4073296.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    42. Carneiro BT, Araujo JF. The food-entrainable oscillator: a network of interconnected brain structures entrained by humoral signals? Chronobiol Int. 2009 Oct; 26(7):1273-89. PMID: 19916831.
      Citations: 35     Fields:    Translation:AnimalsCells
    43. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 01; 27(25):4076-81. PMID: 19636008; PMCID: PMC4371138.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    44. Araujo J, Logothetis C. Targeting Src signaling in metastatic bone disease. Int J Cancer. 2009 Jan 01; 124(1):1-6. PMID: 18942061.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    45. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim SJ, Wang Z, Gallick GE. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008 May 01; 68(9):3323-33. PMID: 18451159.
      Citations: 117     Fields:    Translation:HumansAnimalsCells
    46. Kashanchi F, Araujo J, Doniger J, Muralidhar S, Hoch R, Khleif S, Mendelson E, Thompson J, Azumi N, Brady JN, Luppi M, Torelli G, Rosenthal LJ. Human herpesvirus 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53. Oncogene. 1997 Jan 23; 14(3):359-67. PMID: 9018122.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    47. Muralidhar S, Doniger J, Mendelson E, Araujo JC, Kashanchi F, Azumi N, Brady JN, Rosenthal LJ. Human cytomegalovirus mtrII oncoprotein binds to p53 and down-regulates p53-activated transcription. J Virol. 1996 Dec; 70(12):8691-700. PMID: 8970996; PMCID: PMC190964.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    48. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America. 113:11919-11924.
    49. The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study. BMC Cancer. 16.
    50. Skeletal tumor burden on baseline 18F-fluoride PET/CT predicts bone marrow failure after 223Ra therapy. Clinical Nuclear Medicine. 41:268-273.
    51. Kidney cancer. 133-142.
    52. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. Journal of Clinical Oncology. 34:1652-1659.
    53. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. Scientific Reports. 6.
    ARAUJO's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (250)
    Explore
    _
    Co-Authors (45)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _